Abagovomab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | (imitates CA-125) |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | subcutaneous |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Excretion | N/A |
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| (what is this?) (verify) | |
Abagovomab is an investigational new drug that is being developed by the pharmaceutical company Menarini for the treatment of ovarian cancer.
Abagovomab is a mouse anti-idiotype monoclonal antibody whose variable epitope mimics the tumour-associated antigen CA-125, which is highly expressed in epithelial ovarian cancer. Unlike antibodies that directly target CA-125, abagovomab acts as a "surrogate" antigen. By mimicking CA-125, it prompts the immune system to recognize and attack tumour cells expressing this protein. It is hoped that this immune response will eliminate residual tumour cells and help prevent disease recurrence.